Table 1.
Demographic and clinical characteristics of recruited MS patients and healthy controls. Age, disease duration (in years), Expanded Disability Status Scale (EDSS) and duration under therapy (in months) are presented as mean. SD: standard deviation, SEM: standard error of the mean. COVID: Coronavirus Disease 2019. DMF: dimethyl fumarate. Booster: third SARS-CoV-2 vaccination.
| MS | HC | |
|---|---|---|
| Number | 10 | 9 |
| Male (%) | 3 (30%) | 2 (22%) |
| Female (%) | 8 (70%) | 7 (78%) |
| Age ± SD (range) | 45 ± 11 (28 to 63) | 41,5 ± 9,3 (26 to 50) |
| Disease duration ± SD (range) | 12.6 ± 9.9 (3 to 33) | NA |
| Disease activity (during last 6 months) | ||
| Relapse | 2 (20%) | NA |
| No relapse | 8 (80%) | NA |
| EDSS ± SD (range) | 2,3 ± 1,2 (1 to 4) | NA |
| EDSS median | 2 | NA |
| EDSS ± SEM | 2,3 ± 0,37 | NA |
| COVID prior blood sampling | – | – |
| Treatment | MS total 10 | HC total 9 |
| During first and second vaccination | ||
| DMF | 2 (20%) | – |
| Interferon beta-1a | 1 (10%) | – |
| Natalizumab | 2 (20%) | – |
| Cladribrin | 1 (10%) | – |
| Fingolimod | 2 (20%) | – |
| Ozanimod | 1 (10%) | – |
| No therapy | 1 (10%) | 9 (100%) |
| During Booster | ||
| Ofatumumab | 10 (100%) | – |
| Duration under therapy ± SD (range) | 3,5 ± 0,7 (2 to 4) | – |
| no therapy | – | 9 (100%) |
| Vaccination | MS total 10 | HC total 9 |
| Basic Immunisation | ||
| Comirnaty (Pfizer/Biontech) | 10 (100%) | 6 (67%) |
| Vaxzevria (Astrazeneca) | – | – |
| Spikevax (Moderna) | – | 2 (22%) |
| Mixed (Vaxzevria and Comirnaty) | – | 1 (11%) |
| Booster | ||
| Comirnaty (Pfizer/Biontech) | 8 (80%) | 7 (78%) |
| Spikevax (Moderna) | 2 (20%) | 2 (22%) |